VFA
DRNA

Virtus Fund Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Virtus Fund Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-303
Closed -$7K – 2146
2014
Q2 		$7K Buy
+303
New +$5.49K ﹤0.01% 2811

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Virtus Fund Advisers's DRNA Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2014, closing a stake of 303 shares — an estimated $7K sold.

Virtus Fund Advisers first reported a position in DRNA in Q2 2014 and held it in 1 quarter. The position peaked at $7K in Q2 2014. 40 funds tracked by Wall St. Rank hold DRNA as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 303 Dicerna Pharmaceuticals, Inc. shares in Q3 2014, an estimated $7K.
  • Virtus Fund Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $7K in Q2 2014.
  • 40 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.